Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899059 | 0.84 | KIF11 (0.54) | KIF11SMN1; SMN2 | |
| SCHEMBL5899066 | 0.83 | KIF11 (0.54) | KIF11SMN1; SMN2SLC26A6HPGDMEN1 | |
| SCHEMBL5899006 | 0.83 | KIF11 (0.51) | KIF11SMN1; SMN2SLC26A6 | |
| SCHEMBL5899080 | 0.80 | KIF11 (0.52) | KIF11 | |
| SCHEMBL5899000 | 0.79 | KIF11 (0.54) | KIF11 | |
| SCHEMBL4038758 | 0.76 | KIF11 (0.66) | KIF11 | |
| SCHEMBL5898996 | 0.76 | KIF11 (0.58) | KIF11SMN1; SMN2SLC26A6HPGDMEN1 | |
| SCHEMBL4040410 | 0.75 | KIF11 (0.60) | KIF11SMN1; SMN2HPGD | |
| SCHEMBL4038239 | 0.75 | KIF11 (0.76) | KIF11 | |
| SCHEMBL4040581 | 0.74 | KIF11 (0.53) | KIF11SMN1; SMN2SLC26A6HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022850-B2 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | CCNB1, CCNB2, CCNI | KIF11 257/4885SMN1; SMN2 1670/4885SLC26A6 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.